Study #2025-0768
A phase 1 first-in-human open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of ERAS-4001 monotherapy and in combination in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
ERAS-4001, ERAS-4001 in combination
Description
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Solid Tumors
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.